This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) (NCT03188523), a non-randomized phase 1 study. The primary outcome is Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) at 168 Hours Post-Dose.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT03188523 |
| Phase | Phase 1 |
| Condition | HIV-1 Infection |
| Allocation | Non-Randomized |
| Design model | Parallel |
| Masking | None (open label) |
| Enrollment | 12 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Merck Sharp & Dohme LLC |
| Results posted | Yes |
2. Clinical Question
Population
ART-naïve participants with HIV-1 infection were eligible for the study. The registry record lists an enrollment of 12. It describes the primary analysis population as “all randomized participants,” although the stated allocation is non-randomized; that wording leaves the population definition unclear.
Intervention
The intervention was a single oral dose of MK-8504. The record describes panels for 100 mg, 240 mg, and doses at or below 240 mg. Its stated aims included evaluating safety, tolerability, pharmacokinetics, and antiretroviral activity.
Comparator
The primary hypothesis refers to comparison with placebo. However, the arm descriptions identify MK-8504 dose panels, and a placebo arm is not described in the listed interventions. The registry classifies allocation as non-randomized and cautions that the arms are not a like-for-like control comparison.
Primary question
The primary endpoint is change from baseline in plasma HIV-1 RNA, measured in log10 copies/mL, at 168 hours after dosing. The question is whether MK-8504 is associated with a change in this viral-load measure over that interval. The endpoint estimate and its confidence interval are not reported in the registry record, so the size and precision of the observed change cannot be described from this record.
This is an early-phase, single-dose study rather than a randomized comparison of treatment strategies. The registry record identifies HIV-1 infection as the condition and gives the trial title as a study of MK-8504 in antiretroviral-naïve participants. Its hypothesis names placebo as the comparator, but the listed intervention descriptions do not establish a placebo group. That distinction matters: a change from baseline within dose panels is not, by itself, evidence of a difference from placebo or another concurrent control. The record also identifies pharmacokinetic outcomes, including measures of exposure, peak concentration, timing, half-life, clearance, and distribution. Numerical results for those outcomes are not reported in the registry record presented for this analysis. The available record therefore establishes the research question and outcome definitions, but not the numerical evidence needed to characterize the endpoint response or compare dose groups.
3. Trial Design
The trial is listed as Phase 1, completed, non-randomized, unmasked, and using a parallel model. Enrollment is recorded as 12 participants. The registry record lists a start date of 2017-09-08 and a primary completion date of 2018-05-21. These dates describe the registry timeline; they do not establish how long each participant was followed beyond the stated endpoint timing.
The intervention was MK-8504 administered as a single oral dose. The arm descriptions name Panel A at 100 mg, Panel B at 240 mg, and Panels C and D at doses at or below 240 mg. The available record does not specify the dose actually received by each participant in Panels C and D, nor does it provide panel-level enrollment counts for those panels. It lists only MK-8504 as an intervention. Although the primary hypothesis refers to placebo, a placebo arm is not described among the listed interventions.
Because allocation is designated non-randomized and masking is listed as none, the study should not be interpreted as a blinded randomized efficacy comparison. The registry record expressly cautions that the arms are not a like-for-like control comparison. Differences across dose panels may reflect factors other than dose, and the record does not give enough detail to characterize those factors. No protocol description or sample-size justification is reported in the registry record.
The primary endpoint is a modeled change in plasma HIV-1 RNA from baseline to 168 hours post-dose. The record states that measurements from participants in each panel were pooled and analyzed with a longitudinal data analysis model. It names a least-squares mean as the summary and a 95% confidence interval as the dispersion measure. Secondary outcomes concern plasma pharmacokinetics of MK-8504. The record lists 23 outcome measures and 4 analyses, but does not describe the full analysis plan, the role of each analysis, or any adjustment for multiple testing.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Twelve participants infected with Human Immunodeficiency Virus 1 (HIV-1) were enrolled into Panels A and B. Due to an earlier than anticipated achievement of the study primary study objectives, Panels C and D were not conducted and no participants were enrolled in these panels.
Overall Study
| Stage | MK-8504 100 mg (Panel A) | MK-8504 240 mg (Panel B) | MK-8504 ≤240 mg (Panel C) | MK-8504 ≤240 mg (Panel D) |
|---|---|---|---|---|
| STARTED | 6 | 6 | 0 | 0 |
| COMPLETED | 6 | 6 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 |
Analysis population for the primary outcome, as defined in the registry: All randomized participants
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | MK-8504 100 mg (Panel A) | MK-8504 240 mg (Panel B) | Total |
|---|---|---|---|---|
| Participants analysed | 6 | 6 | 12 | |
| Age, Continuous | Years | 31.7 (SD 6.0) | 35.5 (SD 7.0) | 33.6 (SD 6.6) |
| Sex: Female, Male: Female | Participants | 0 | 0 | 0 |
| Sex: Female, Male: Male | Participants | 6 | 6 | 12 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 0 | 1 | 1 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 6 | 5 | 11 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 0 | 1 | 1 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): White | Participants | 6 | 3 | 9 |
| Race (NIH/OMB): More than one race | Participants | 0 | 2 | 2 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
| Baseline Plasma HIV-1 Ribonucleic Acid (RNA) | Log10 copies/mL | 4.31 (SD 0.34) | 4.60 (SD 0.64) | 4.45 (SD 0.51) |
6. Primary Endpoint
The registry lists the primary outcome as Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) at 168 Hours Post-Dose, measured over Baseline, 168 hours post-dose.
| Element | Registry entry |
|---|---|
| Result type | Least Squares Mean |
| Measure of spread | 95% Confidence Interval |
| Unit | log10 (copies/mL) |
| Endpoint classification | Continuous Endpoint |
The primary endpoint is change from baseline in plasma HIV-1 RNA at 168 hours after a single dose. HIV-1 RNA in plasma is used as a measure of viral load; expressing the measurement in log10 copies/mL puts the endpoint on a logarithmic scale. The result is defined as a change in that scale, rather than a raw count of copies. The registry record states that plasma samples were collected after dosing and that the change from baseline to the specified post-dose time was determined for each treatment group.
The use of a defined post-dose time gives the endpoint a consistent point for describing short-term antiretroviral activity in this single-dose study. A baseline-referenced measure also describes within-participant change over the stated interval. The record reports that the analysis used a longitudinal data analysis model and summarized results as least-squares means with 95% confidence intervals. In general, a least-squares mean is a model-based estimate; its interpretation depends on the model and the data included. A confidence interval communicates uncertainty around an estimate, rather than guaranteeing that the true value lies within its limits.
The numerical least-squares mean and confidence interval are not reported in the registry record. Consequently, the magnitude, direction, and precision of the endpoint change cannot be characterized from this record. The endpoint definition also does not, on its own, establish a placebo-adjusted effect: the record does not describe a placebo arm among the listed interventions, and the allocation is non-randomized.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record defines a clinically relevant laboratory endpoint for an early-phase, single-dose study: change in plasma HIV-1 RNA from baseline to 168 hours post-dose. It identifies the intended summary as a least-squares mean and the uncertainty measure as a 95% confidence interval. However, neither the endpoint estimate nor its confidence interval is reported in the registry record. There is therefore no numerical primary result in this record to interpret for size, direction, or precision.
The record’s primary hypothesis refers to superior antiretroviral activity compared with placebo. That hypothesis should be distinguished from the design details that are actually listed. Allocation is classified as non-randomized, and the intervention descriptions identify MK-8504 dose panels rather than a placebo arm. The registry explicitly warns that the arms are not a like-for-like control comparison. Without a clearly described concurrent comparator and a reported contrast, the hypothesis cannot be read as evidence that a placebo comparison was performed or that a treatment difference was estimated.
The endpoint description says that participants’ measurements within each panel were pooled and analyzed using a longitudinal data analysis model. In general, longitudinal models can use measurements collected over time and account for their relationship within participants. Their estimates depend on the model specification and the observations available. The registry record does not report the model details, assumptions, handling of incomplete measurements, or diagnostic checks. Those omissions limit independent assessment of how the model produced the stated least-squares means.
The enrollment of 12 is small in absolute terms and the record describes a Phase 1 study. Those features are consistent with an early-stage investigation focused on safety, tolerability, pharmacokinetics, and initial activity, but they do not establish the trial’s statistical power or its design rationale. A sample-size justification is not reported in the registry record. Planning illustrations based on an observed effect, where displayed with the analysis, are not observed power and should not be mistaken for a design calculation from the trial protocol.
Interpretation of dose-panel patterns is also constrained by non-random allocation and the absence of a like-for-like control comparison. The record lists several dose panels, but does not supply the panel-specific primary estimates in the registry record for this analysis. It is not possible to say whether changes differed by dose, how stable those differences were, or whether they were statistically distinguishable.
In short, the record identifies what the investigators intended to measure and how they described the summary measure. It does not report the numerical primary outcome, a placebo-adjusted estimate, or sufficient model details to evaluate those quantities. Any conclusion about the observed antiretroviral activity or the precision of an effect would go beyond what is reported in the registry record.
9. Statistical Methods Explained
The endpoint is a continuous measure: change in plasma HIV-1 RNA, expressed in log10 copies/mL. For a continuous outcome, a mean summarizes the central tendency of measurements, while a confidence interval describes uncertainty around an estimated mean. The registry specifies a least-squares mean and a 95% confidence interval. A least-squares mean is generally a model-based mean, which may account for features of the analysis model; it is not necessarily identical to a simple arithmetic average. The specific model terms and estimation details are not reported in the registry record.
What does the longitudinal model contribute?
The record says that log10 plasma HIV-RNA measurements from participants in each panel were pooled and analyzed using a longitudinal data analysis model. In general, longitudinal methods are used when measurements are collected repeatedly over time. They can model how measurements change and account for the fact that observations from the same participant are related rather than independent. This can make use of the sequence of observations rather than treating each measurement as unrelated.
The usefulness of a longitudinal model depends on how it is specified and on the pattern of available observations. General issues include the selected time structure, the covariance assumptions, the way treatment or panel is represented, and the handling of missing measurements. These details are not reported in the registry record. The record also does not report whether model assumptions were assessed or whether any alternative analyses were conducted. Without these details, the model description identifies a broad analytical approach but does not allow full replication or evaluation of its assumptions.
How should the confidence interval be read?
In general, a confidence interval gives a range of values compatible with the data and the statistical model under the method’s assumptions. A narrower interval indicates greater precision than a wider interval, while neither width nor location alone establishes clinical importance. The registry names a 95% confidence interval for the primary outcome, but does not report its endpoints or the least-squares mean. It is therefore not possible to assess the interval’s width, whether it includes no change, or how precisely the change was estimated.
A confidence interval around a within-panel change is not automatically an interval for a between-group contrast. A comparison with placebo would require an appropriate estimate of the difference between the MK-8504 group and placebo, with its own uncertainty. The record’s stated hypothesis mentions placebo, but the listed intervention descriptions do not identify a placebo group, and allocation is non-randomized. The registry also cautions that the arms are not a like-for-like control comparison. Thus, the endpoint definition and model summary should not be treated as proof of a placebo-adjusted estimate.
Why does the non-randomized allocation matter?
In general, random allocation helps balance measured and unmeasured participant characteristics across groups on average. With non-random allocation, group membership can be related to participant characteristics, timing, or other factors. A difference between groups may therefore reflect those factors as well as the intervention. The registry record explicitly identifies non-randomized allocation and warns against treating the arms as a like-for-like control comparison. This caution is especially important when interpreting any apparent pattern across dose panels.
The record lists a parallel model and no masking. In general, parallel groups consist of different participants receiving different assigned interventions, while masking concerns whether participants or study personnel know the assigned treatment. Those design labels alone do not resolve potential confounding or establish the comparability of panels. Allocation procedures and further implementation details are not reported in the registry record.
What do the planning illustrations represent?
The sample-size assumptions describe planning illustrations based on the observed effect, a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. They define the effect to detect as a stated fraction of the observed effect. Such calculations are prospective planning illustrations, not observed power. They do not demonstrate that the study was adequately powered, and they are distinct from the actual enrollment of 12. The trial’s own sample-size justification is not reported in the registry record. The numerical endpoint estimate needed to understand the observed effect is also not reported in the registry record, so the planning assumptions should not be interpreted as supplying an unreported primary result.
More generally, a planning calculation depends on assumptions about the target effect, variability, allocation, analysis method, and error rate. Changing an assumption can change the planning result. The registry record’s brief description does not establish whether its planning illustration matches the protocol design, and it explicitly characterizes the illustration as not the trial’s own design. It should therefore be read as a statistical planning aid rather than evidence about the trial’s achieved precision or results.
What information is needed for a fuller assessment?
A fuller statistical assessment would require the primary estimates and confidence intervals, participant counts contributing to each analysis, model specification, and details on missing observations. It would also require the planned approach to multiple outcomes and analyses, and clarification of the analysis population, especially because the record says “all randomized participants” while listing non-randomized allocation. These items are not reported in the registry record. The broad methods description can explain the intended endpoint and summary, but not reproduce or validate the analysis.
10. Multiplicity, Missing Data and Analysis Populations
The registry record lists 23 outcome measures and 4 analyses. The primary endpoint is change in plasma HIV-1 RNA at 168 hours post-dose, while the secondary outcomes include pharmacokinetic measures such as exposure over specified intervals, time to maximum concentration, maximum concentration, apparent terminal half-life, clearance, and volume of distribution. When multiple outcomes or analyses are examined, the chance of at least one apparently unusual result can increase. In general, a multiplicity plan may specify which outcome is primary, how secondary outcomes are interpreted, and whether or how statistical testing is adjusted. No multiplicity adjustment or hierarchy is reported in the registry record.
The record does not report the handling of missing outcome measurements, the number of participants contributing to each endpoint analysis, or any imputation or sensitivity-analysis approach. These details matter because the analysis population and missing-data assumptions can affect model estimates and their uncertainty. The endpoint description says measurements were pooled and analyzed with a longitudinal model, but that statement does not specify how incomplete participant data were handled.
The primary population is described as “all randomized participants,” while the allocation is classified as non-randomized. This terminology creates uncertainty about which participants were included in the primary analysis and how the analysis population was defined. Clarification is not reported in the registry record. Interim analyses and stopping rules are also not reported. Their absence from the record should be treated as missing documentation, not as evidence that they did or did not occur.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| MK-8504 100 mg (Panel A) | 0 | 6 | 0.0% |
| MK-8504 240 mg (Panel B) | 0 | 6 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| MK-8504 100 mg (Panel A) | 0 of 6 |
| MK-8504 240 mg (Panel B) | 0 of 6 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| MK-8504 100 mg (Panel A) | 5 of 6 |
| MK-8504 240 mg (Panel B) | 6 of 6 |
Most frequent non-serious adverse event terms
| Event term | Organ system | MK-8504 100 mg (Panel A) | MK-8504 240 mg (Panel B) |
|---|---|---|---|
| Headache | Nervous system disorders | 2 of 6 | 3 of 6 |
| Diarrhoea | Gastrointestinal disorders | 2 of 6 | 1 of 6 |
| Fatigue | General disorders | 1 of 6 | 1 of 6 |
| Nasopharyngitis | Infections and infestations | 1 of 6 | 1 of 6 |
| Myalgia | Musculoskeletal and connective tissue disorders | 0 of 6 | 2 of 6 |
| Dizziness | Nervous system disorders | 0 of 6 | 2 of 6 |
| Abnormal dreams | Psychiatric disorders | 0 of 6 | 2 of 6 |
| Abdominal pain | Gastrointestinal disorders | 0 of 6 | 1 of 6 |
| Dyspepsia | Gastrointestinal disorders | 0 of 6 | 1 of 6 |
| Flatulence | Gastrointestinal disorders | 0 of 6 | 1 of 6 |
The serious adverse event figures listed are for MK-8504 100 mg (Panel A) and MK-8504 240 mg (Panel B). Each group has 6 participants at risk for serious adverse events, and 0 serious adverse events are recorded in each. The record lists 0 deaths in each of these groups. No top serious-event terms are listed. These are descriptive figures for the groups and outcomes specified in the registry record; they do not establish that no serious events occurred in any other panel or at any unlisted time.
Other adverse events are recorded for 5 of 6 participants in Panel A and 6 of 6 participants in Panel B. The registry separates these figures from the serious adverse event counts, so they should not be conflated. The record does not provide the specific terms for those other events in the registry record for this analysis, nor does it describe their severity, timing, or relation to treatment.
In general, zero observed serious events in a small group does not show that the underlying risk is zero. These counts describe what was recorded among the participants at risk in the listed groups. They should be interpreted alongside the study’s Phase 1, single-dose design and enrollment of 12, without drawing conclusions about safety beyond the observed groups and reported outcomes.
12. What the Result Does, and Does Not, Mean
The registry record establishes that investigators studied single-dose MK-8504 in ART-naïve participants with HIV-1 infection and designated change in plasma HIV-1 RNA at 168 hours as the primary endpoint. It also identifies pharmacokinetic measures and adverse-event summaries. These details describe the study question and outcome framework, not the numerical primary result.
The primary endpoint estimate and its 95% confidence interval are not reported in the registry record. Consequently, the direction and magnitude of the change, and the precision with which it was estimated, cannot be assessed from this record. The primary hypothesis refers to comparison with placebo, but the listed interventions describe MK-8504 dose panels and do not identify a placebo arm. The record also labels allocation non-randomized and warns that the arms are not a like-for-like control comparison. A within-panel change should therefore not be presented as a demonstrated placebo-adjusted difference.
The record’s safety figures show 0 serious adverse events and 0 deaths among 6 participants at risk in each of the two listed dose groups, alongside other adverse events in 5 of 6 and 6 of 6 participants, respectively. These are descriptive observations from the specified groups. They do not establish the absence of risk, and the other adverse events are not described in detail in the registry entries.
This study’s Phase 1 status, single-dose design, and enrollment of 12 frame the scope of what it can address. The registry record does not report the sample-size justification, a detailed statistical plan, the approach to missing data, or a multiplicity procedure. It also uses “all randomized participants” to describe the primary population despite classifying allocation as non-randomized. Taken together, these limits mean that the record supports a description of the study design and outcomes, but not a conclusion about treatment effect, comparative efficacy, or broader safety.
13. Why This Trial Matters Statistically
This trial is statistically notable because it combines a defined short-term virologic endpoint with a non-randomized, single-dose design. The primary endpoint—change in plasma HIV-1 RNA at 168 hours—offers a specified measure for examining initial antiretroviral activity. The registry describes a longitudinal model and least-squares mean with a 95% confidence interval, which makes the intended form of the analysis clear at a broad level.
The design also illustrates why an endpoint and a hypothesis are not enough to establish a treatment comparison. The stated hypothesis refers to placebo, while the intervention descriptions list MK-8504 panels and allocation is classified as non-randomized. The registry warns that the arms are not a like-for-like control comparison. This makes it important to separate a modeled change within a panel from a contrast against a concurrent control, and to avoid interpreting dose-panel differences as causal effects without suitable design and analysis support.
The record’s reporting gaps matter for statistical interpretation. It does not report the numerical primary estimate or confidence interval, the sample-size justification, missing-data methods, or multiplicity procedures. It also describes the primary population as “all randomized participants” despite the non-randomized allocation label. These omissions prevent assessment of precision, reproducibility, and the relation between the stated hypothesis and the analysis actually performed.
The value of examining the trial statistically is therefore not in making claims beyond the record. It is in recognizing how design, outcome definition, model assumptions, uncertainty, and reporting completeness jointly determine what can be inferred. The study provides a framework for early-phase investigation, while its registry description leaves essential result and analysis details unreported.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The main trial-specific limitation is that the numerical primary endpoint result is not reported in the registry record. Without the least-squares mean and 95% confidence interval, neither the size nor precision of the change can be evaluated. The registry’s hypothesis refers to placebo, but no placebo arm appears in the listed interventions. It also states that allocation is non-randomized and that arms are not a like-for-like control comparison, limiting interpretation of any cross-panel differences.
The record lists a total enrollment of 12, but does not report panel-specific enrollment for all four described panels or the number of participants contributing to the primary analysis. The primary population label, “all randomized participants,” is difficult to reconcile with the non-randomized allocation classification. The record does not explain this terminology or define the analysis population in further detail.
Although a longitudinal data analysis model is named, its specification, assumptions, handling of missing data, and diagnostic assessment are not reported. Multiplicity handling for the 23 outcome measures and 4 analyses is also not reported. A protocol-based sample-size justification, interim-analysis plan, and detailed analysis plan are not reported in the registry record. These limitations are specific to the available description and prevent an independent appraisal of the reported statistical methods or conclusions.
The safety information is limited to serious adverse event and other adverse event counts for the two listed dose groups. Specific other-event terms are not reported in the registry record, and the summary does not support extrapolation to unlisted panels or longer-term exposure. The study is described as a single-dose Phase 1 trial, so its scope is inherently different from a comparative treatment study over an extended treatment period.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) — NCT03188523.
- Registry record last updated 2019-07-15; status last verified 2019-05.
- Results first posted 2019-07-15.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry record describes NCT03188523, a completed Phase 1 study of single-dose MK-8504 in ART-naïve participants with HIV-1 infection. Enrollment is recorded as 12. The design is listed as non-randomized, unmasked, and parallel. The primary endpoint is change from baseline in plasma HIV-1 RNA at 168 hours post-dose, summarized as a least-squares mean with a 95% confidence interval using a longitudinal data analysis model.
The record lists four MK-8504 dose panels and pharmacokinetic secondary outcomes. Its primary hypothesis refers to placebo, but a placebo arm is not identified in the listed interventions; the registry cautions against treating the arms as a like-for-like control comparison. Numerical primary results, detailed model specifications, multiplicity handling, missing-data methods, and a trial-based sample-size justification are not reported in the registry record. Serious adverse event and death counts are reported for the two listed dose groups, together with other adverse event counts.